Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 7/20 | 0.45 |
| ▸ | FLT1 | P17948 | 7/20 | 0.45 |
| ▸ | TEK | Q02763 | 5/20 | 0.45 |
| ▸ | KDR | P35968 | 7/20 | 0.42 |
| ▸ | CSF1R | P07333 | 3/20 | 0.42 |
| ▸ | FLT4 | P35916 | 3/20 | 0.42 |
| ▸ | KIT | P10721 | 3/20 | 0.42 |
| ▸ | FLT3 | P36888 | 3/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | FYN | P06241 | 2/20 | 0.42 |
| ▸ | LYN | P07948 | 2/20 | 0.42 |
| ▸ | BLK | P51451 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27780673 | 0.94 | RIPK1 (0.42) | RIPK1FLT1TEKKDRCSF1R | |
| SCHEMBL15221994 | 0.89 | KDR (0.42) | RIPK1FLT1TEKKDRCSF1R | |
| SCHEMBL3620600 | 0.89 | RIPK1 (0.44) | RIPK1FLT1TEKKDRCSF1R | |
| SCHEMBL3619710 | 0.88 | TEK (0.57) | RIPK1FLT1TEKKDRCSF1R | |
| SCHEMBL3621408 | 0.87 | FLT1 (0.40) | RIPK1FLT1TEKKDRCSF1R | |
| SCHEMBL275476 | 0.85 | RIPK1 (0.45) | RIPK1FLT1TEKKDRCSF1R | |
| SCHEMBL275201 | 0.84 | RIPK1 (0.44) | RIPK1FLT1TEKKDRCSF1R | |
| SCHEMBL275915 | 0.83 | BTK (0.46) | RIPK1FLT1TEKKDRCSF1R | |
| SCHEMBL3612902 | 0.83 | RIPK1 (0.42) | RIPK1FLT1TEKKDRCSF1R | |
| SCHEMBL276394 | 0.82 | KDR (0.47) | RIPK1FLT1TEKKDRCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225809-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225809-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8338595-B2 | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338595-B2 | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338595-B2 | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| CN-1993361-B | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORP | 2010-05-26 | — | — | CN | disclosed |
| EP-1765823-B1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORP (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-1765823-B1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORP (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20100075958-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075958-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075958-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-7563791-B2 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563791-B2 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563791-B2 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070208013-A1 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208013-A1 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208013-A1 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075958-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | MKI67, TK2, CDK4 | RIPK1 1357/4885FLT1 6/4885TEK 29/4885 |
| US-20130225809-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | MKI67, TK2, CDK4 | RIPK1 1357/4885FLT1 6/4885TEK 29/4885 |
| US-20070208013-A1 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | MKI67, CCNA1, CCNI | RIPK1 3512/4885FLT1 6/4885TEK 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.